Chemo-Nonresponsive Telangiectatic Osteosarcoma With Oligometastatic Recurrence Managed With Multimodality Therapy Including Stereotactic Ablative Body Radiotherapy (SABR): A Case Report With a Pathologic Treatment Effect.
Saved in:
| Title: | Chemo-Nonresponsive Telangiectatic Osteosarcoma With Oligometastatic Recurrence Managed With Multimodality Therapy Including Stereotactic Ablative Body Radiotherapy (SABR): A Case Report With a Pathologic Treatment Effect. |
|---|---|
| Authors: | Orr WS; SOM-Surgery-Transplant, University of Mississippi Medical Center, Jackson, USA., Vijayakumar S; Radiology, Ochsner Clinic Foundation and Ochsner Health, New Orleans, USA.; Radiation Oncology, Manipal Comprehensive Cancer Care Centre, Kasturba Medical College and Manipal Academy of Higher Education, Manipal, IND.; Cancer Care, Cancer Care Advisors and Consultants LLC, Ridgeland, USA., Al Hmada Y; Pathology, University of Mississippi Medical Center, Jackson, USA., Mobit P; Radiation Oncology, University of Mississippi Medical Center, Jackson, USA., Collier AB; Pediatric Hematology-Oncology, Nemours Children's Health, Jacksonville, USA., Barr J; Orthopedic Oncology, University of Mississippi Medical Center, Jackson, USA., De Delva PE; Surgery, University of Mississippi Medical Center, Jackson, USA., Davis DB; Pediatric Oncology, University of Mississippi Medical Center, Jackson, USA., Yang CC; Radiation Oncology, University of Mississippi Medical Center, Jackson, USA., Nittala R; Radiation Oncology, University of Mississippi Medical Center, Jackson, USA. |
| Source: | Cureus [Cureus] 2026 Mar 31; Vol. 18 (3), pp. e106242. Date of Electronic Publication: 2026 Mar 31 (Print Publication: 2026). |
| Publication Type: | Case Reports; Journal Article |
| Journal Info: | Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
